Neural Stem Cells (NSCs) are a distinct group of cells present in the embryonic and adult mammalian central nervous system (CNS) that are able to differentiate into neurons, astrocytes and oligodendrocytes. As NSC proliferation declines with age, factors that regulate this process need to be defined. To search for NSC regulatory factors, we performed a quantitative shotgun proteomics study that revealed that members of the High Mobility Group B (HMGB) family are highly expressed in NSCs. Using a neurosphere assay, we report the differential expression of HMGB 1, 2, 3, and 4 mRNAs in proliferating NSCs isolated from various time points during embryonic development, as well as the dynamic expression of HMGB1 and B2 mRNAs and proteins in differentiating embryonic NSCs. Expression of HMGB2 underwent the most dramatic changes during the developmental ages examined; as a result, we assessed its role in NSC proliferation and differentiation. We report the predominance of small diameter HMGB2-/- neurospheres in comparison to wild-type, which correlated with increased proliferation in these smaller HMGB2-/- neurospheres. Our data suggest that HMGB2 plays a regulatory role in NSC cell proliferation and maintenance pathways.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708756 | PMC |
http://dx.doi.org/10.1186/1477-5956-11-18 | DOI Listing |
Cad Saude Publica
January 2025
Faculdade de Odontologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil.
This scoping review maps primary prevention and early detection strategies for oral and oropharyngeal cancer across national cancer plans and noncommunicable disease plans from all World Health Organization Member States. Following PRISMA-ScR guidelines, bibliographic search was performed on key organization websites until March 2023. Of the 194 countries assessed three had subnational plans, resulting in 264 self-governing political entities and similar with revised plans.
View Article and Find Full Text PDFRev Gaucha Enferm
January 2025
Universidade Federal de São João del-Rei (UFSJ), Faculdade de Enfermagem, Programa de Pós-Graduação em Enfermagem. Divinópolis, Minas Gerais, Brasil.
Objective: To understand the relationships that promote and threaten family hope during pregnancy and in the care of high-risk newborns.
Method: Qualitative research, guided by the theoretical framework of Understanding the Complex Nature of Hope, carried out between December 2021 and March 2022, with 28 members of 14 families attended at a multidisciplinary outpatient clinic for at-risk newborns in Minas Gerais, Brazil. Data obtained from interviews in thematic oral history allowed the construction of narratives, genograms and ecomaps, which were subjected to deductive thematic analysis procedures.
Rev Col Bras Cir
January 2025
- School of Medical Sciences Orebro university, Department of Surgery - Orebro - OR - Suécia.
Introduction: Hemorrhage is the leading cause of preventable deaths in trauma patients, resulting in 1.5 million deaths annually worldwide. Traditional trauma assessment follows the ABC (airway, breathing, circulation) sequence; evidence suggests the CAB (circulation, airway, breathing) approach to maintain perfusion and prevent hypotension.
View Article and Find Full Text PDFJ Health Serv Res Policy
January 2025
Assistant Professor, Department of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK.
Objectives: Urinary tract infections (UTIs) can negatively impact quality of life, especially when recurring. Patients often seek medical advice to relieve painful symptoms. UTIs are also the second most common reason antibiotics are prescribed in English primary care.
View Article and Find Full Text PDFDermatol Ther (Heidelb)
January 2025
1st Department of Dermatology and Venereology, Medical School of Athens, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Introduction: Results from randomized controlled trials of upadacitinib, a Janus kinase (JAK) inhibitor, have led to its approval for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 12 years. The aim of this study was to report the effectiveness and safety of upadacitinib in real-world settings over a period of 96 weeks.
Methods: This retrospective study included all patients treated with upadacitinib at our centre between April 2022 and September 2024.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!